Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.

Abstract

OTS11101 is a novel peptide vaccine that acts as an angiogenesis inhibitor by inducing cytotoxic T lymphocyte (CTL) cells that specifically target vascular endothelial cells expressing vascular endothelial growth factor (VEGF) receptor 1. We conducted a phase I study to evaluate the safety, tolerability, maximum tolerated dose, and pharmacodynamic biomarker status of this vaccine. Nine patients with advanced solid tumors received 1.0, 2.0, or 3.0 mg of OTS11101 subcutaneously, once a week in a 28-day cycle. Three patients experienced grade 1 injection site reactions, which were the most frequent adverse events. Grade 2 proteinuria and hypertension each occurred in one patient. As other toxicities were generally mild, the maximum tolerated dose was not reached. Furthermore, we explored the induction of specific activated CTLs, and biomarkers related to angiogenesis. A pharmacodynamics study revealed that induction of specific CTLs was observed for a dose of 2.0 and 3.0 mg. The serum concentrations of soluble VEGF receptor 1 and 2 after vaccination increased significantly compared with baseline. A microarray was performed to give a comprehensive analysis of gene expression, suggesting that OTS11101 vaccination resulted in T cell activation in a clinical setting. In conclusion, OTS11101 was well tolerated in patients up to 3.0 mg once weekly and our biomarker analysis suggested that this anti-angiogenesis vaccine is biologically active.

• Authors: Hidetoshi Hayashi, Takayasu Kurata, Yasuhito Fujisaka, Hisato Kawakami, Kaoru Tanaka, Takafumi Okabe, Masayuki Takeda, Taroh Satoh, Koji Yoshida, Takuya Tsunoda, Tokuzo Arao, Kazuto Nishio, Kazuhiko Nakagawa
• Journal: Cancer science (Cancer Sci) Vol. 104 Issue 1 Pg. 98-104 (Jan 2013) ISSN: 1349-7006 [Electronic] England
• PMID: 23020774 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2012 Japanese Cancer Association.

Chemical References

• Angiogenesis Inhibitors
• Biomarkers, Tumor
• Cancer Vaccines
• HLA-A*24:02 antigen
• HLA-A24 Antigen
• Vaccines, Subunit
• Vascular Endothelial Growth Factor Receptor-1
• Vascular Endothelial Growth Factor Receptor-2

Topics

• Adult
• Aged
• Angiogenesis Inhibitors (adverse effects, therapeutic use)
• Biomarkers, Tumor
• Cancer Vaccines (administration & dosage, adverse effects, therapeutic use)
• HLA-A24 Antigen (immunology)
• Humans
• Lymphocyte Activation
• Middle Aged
• Neoplasms (metabolism, therapy)
• Neovascularization, Pathologic (therapy)
• T-Lymphocytes, Cytotoxic (immunology)
• Vaccines, Subunit (administration & dosage, adverse effects, therapeutic use)
• Vascular Endothelial Growth Factor Receptor-1 (blood)
• Vascular Endothelial Growth Factor Receptor-2 (blood)